Core Viewpoint - Pomerantz LLP is investigating claims related to potential securities fraud or unlawful business practices involving Necessity Retail REIT, Inc. following its acquisition by Global Net Lease, Inc. [1][2] Group 1: Investigation Details - The investigation focuses on whether Necessity Retail and certain officers or directors engaged in securities fraud or other unlawful business practices [2] - Investors who received shares of Global Net Lease in connection with the merger on September 12, 2023, are encouraged to contact Pomerantz LLP [1] Group 2: Financial Projections and Market Performance - The Offering Materials for the merger projected Adjusted Funds From Operations (AFFO) for the combined company to be $399.8 million for 2024 and $409.0 million for 2025 [4] - Since the merger date, Global Net Lease's share price has declined by over 33% [4]

Core Viewpoint - MarineMax, Inc. is under investigation for potential securities fraud and unlawful business practices following a significant reduction in profit guidance and a sharp decline in stock price [1][3][4]. Financial Performance - On July 24, 2025, MarineMax reported its financial results for Q3 2025, cutting its profit guidance by 50% at the midpoint to a range of $0.45 to $0.95 per share, down from a previous guidance of $1.40 to $2.40 per share [3]. - The CEO attributed the weak retail demand in the recreational marine industry to ongoing economic uncertainty, evolving trade policies, and geopolitical tensions, leading consumers to delay purchases [3]. Stock Market Reaction - Following the announcement of the reduced profit guidance, MarineMax's stock price fell by $4.61, or 16.87%, closing at $22.71 per share on July 24, 2025 [4].

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Geely Automobile Holdings Limited ("Geely" or the "Company") (OTCMKTS: GELYF; GELYY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Geely and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On this news, the value of Geely securities fell sharpl ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Dow Inc. and its officers or directors, following a significant drop in the company's stock price after disappointing financial results for Q2 2025 [1][3]. Financial Performance - Dow reported net sales of $10.1 billion for Q2 2025, which represents a 7% decrease year-over-year and a 3% decline sequentially [3]. - The decline in net sales was attributed to decreases across all operating segments, despite seasonally higher demand in Performance Materials & Coatings [3]. - Following the financial results announcement, Dow's stock price fell by $5.30 per share, or 17.45%, closing at $25.07 per share on July 24, 2025 [3]. Corporate Actions - Dow's CEO announced an adjustment to the company's dividend to maintain a balanced capital allocation framework [3].

Core Viewpoint - A class action lawsuit has been filed against Fiserv, Inc. for alleged violations of securities laws, claiming the company made false and misleading statements regarding its Clover platform and its impact on revenue growth [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased Fiserv securities between July 24, 2024, and July 22, 2025, are encouraged to participate in the lawsuit before the deadline of September 22, 2025 [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against Fiserv - The complaint alleges that Fiserv misled the market by forcing merchants to migrate from its Payeezy platform to the Clover program due to cost issues, which artificially inflated Clover's revenue growth [4]. - The company reportedly lost customers to competitors because of Clover's high prices and poor customer service, indicating that public statements made by Fiserv were materially misleading [4]. - As a result of these misleading statements, investors suffered damages when the truth about Fiserv's business practices was revealed [4].

Core Viewpoint - A lawsuit has been filed against Replimune Group, Inc. and its senior executives for potential violations of federal securities laws, following a significant decline in stock price after the FDA's response regarding the company's lead product candidate RP1 [1][2][5]. Group 1: Company Overview - Replimune is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer treatment, with its lead product candidate being RP1 for melanoma [3]. - The company announced positive results from its IGNYTE Phase 1/2 clinical trial for RP1 in combination with nivolumab on June 6, 2024, and subsequently submitted a biologics license application (BLA) to the FDA based on these results [3]. Group 2: Legal Issues - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors who purchased Replimune securities [2]. - The complaint alleges that the IGNYTE Phase 1/2 trial design was inadequate to produce reliable results, despite the company promoting its outcomes [4]. Group 3: Stock Performance - Following the FDA's Complete Response Letter on July 22, 2025, which indicated that the IGNYTE trial was not considered adequate for substantial evidence of effectiveness, Replimune's stock price fell by more than 75% [5].

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years. A ...

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of Nutex Health Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] - Blue Orca Capital issued a short report alleging that Nutex faces litigation risk due to its relationship with HaloMD, which is involved in a fraudulent scheme against insurance companies [2] - Following the release of the Blue Orca report, Nutex's stock price dropped by $11.18 per share, a decrease of 10.05%, closing at $100.01 per share on July 22, 2025 [3] Group 2 - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud [4]

Core Viewpoint - Encompass Health Corporation is under investigation for potential securities fraud and unlawful business practices following allegations of poor performance in safety measures at its facilities, leading to a significant drop in stock price [1][2][3]. Group 1: Investigation and Allegations - Pomerantz LLP is investigating claims on behalf of investors of Encompass Health Corporation regarding possible securities fraud or unlawful business practices [1]. - The New York Times reported that Encompass's for-profit hospitals perform below average on key safety measures, with 34 facilities rated by Medicare as having significantly worse rates of preventable readmissions [2]. Group 2: Stock Price Impact - Following the publication of the allegations, Encompass's stock price fell by $12.39 per share, representing a 10.35% decrease, closing at $107.28 per share on July 15, 2025 [3].

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Telix Pharmaceuticals Limited regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Company Developments - On July 22, 2025, Telix disclosed that it received a subpoena from the U.S. Securities and Exchange Commission, which is seeking various documents and information related to the company's disclosures about its prostate cancer therapeutic candidates [2]. - Following the news of the subpoena, Telix's American Depositary Receipt (ADR) price fell by $1.70, or 10.44%, closing at $14.58 per ADR on July 23, 2025 [2]. Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, having a long history of fighting for the rights of victims of securities fraud and corporate misconduct [3].